Hemangioblastoma

Hemangioblastoma (also known as capillary hemangioblastoma or Lindau tumor) is a benign, highly vascularized tumor of the central nervous system (CNS) that arises from stromal cells of uncertain origin. These tumors most commonly occur in the cerebellum (posterior fossa), but can also develop in the brainstem, spinal cord, and, rarely, in the retina (retinal hemangioblastoma). Hemangioblastomas account for approximately 1–2.5% of all intracranial tumors and are classified as WHO grade I neoplasms. They can occur sporadically (approximately 75% of cases) or as a manifestation of von Hippel-Lindau (VHL) disease, an autosomal dominant hereditary cancer syndrome caused by mutations in the VHL tumor suppressor gene on chromosome 3p25. Key symptoms depend on tumor location and size. Cerebellar hemangioblastomas commonly present with headache, ataxia (difficulty with balance and coordination), nausea, vomiting, and signs of increased intracranial pressure due to obstruction of cerebrospinal fluid flow, which can lead to hydrocephalus. Spinal cord hemangioblastomas may cause pain, sensory changes, and progressive weakness. A notable feature of hemangioblastomas is their capacity to produce erythropoietin, which can lead to secondary polycythemia (elevated red blood cell count). Tumors are often cystic with a highly vascular mural nodule. The primary treatment for hemangioblastomas is surgical resection, which is often curative for sporadic cases. Complete removal of the mural nodule is typically sufficient, even when a large cyst is present. For tumors that are surgically inaccessible or in patients who are not surgical candidates, stereotactic radiosurgery may be considered. In patients with VHL disease, multiple hemangioblastomas may develop over time, requiring ongoing surveillance with regular MRI imaging and a multidisciplinary management approach. Targeted therapies, including HIF-pathway inhibitors such as belzutifan, have shown promise in VHL-associated tumors and represent an emerging area of treatment. Prognosis is generally favorable following complete surgical excision, though recurrence is possible, particularly in the setting of VHL disease.

Common questions about Hemangioblastoma